Nerissa Kreher
Director/Board Member bij REZOLUTE, INC.
Vermogen: 567 324 $ op 31-03-2024
Profiel
Nerissa C.
Kreher is currently an Independent Director at Rezolute, Inc. She previously held positions as the Head of Medical Affairs and Clinical Development at Alexion Pharmaceuticals, Inc., Zafgen, Inc., EMD Serono, Inc., and Shire Human Genetic Therapies, Inc. She also served as the Chief Medical Officer at Avrobio, Inc., Tiburio Therapeutics, Inc., and is currently the Chief Medical Officer at Entrada Therapeutics, Inc. Dr. Kreher obtained a doctorate degree from East Carolina University, a graduate degree from Indiana University, an MBA from Northeastern University, and undergraduate degrees from The University of North Carolina at Chapel Hill and The University of North Carolina at Charlotte.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ENTRADA THERAPEUTICS INC
0.12% | 06-09-2023 | 40 037 ( 0.12% ) | 567 324 $ | 31-03-2024 |
REZOLUTE, INC.
-.--% | 18-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Nerissa Kreher
| Bedrijven | Functie | Begin |
|---|---|---|
| REZOLUTE, INC. | Director/Board Member | 02-03-2021 |
Eerdere bekende functies van Nerissa Kreher
| Bedrijven | Functie | Einde |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-02-2024 |
Tiburio Therapeutics, Inc.
 Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01-10-2020 |
| AVROBIO, INC. | Chief Tech/Sci/R&D Officer | 17-12-2018 |
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-07-2016 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Nerissa Kreher
| East Carolina University | Doctorate Degree |
| Indiana University | Graduate Degree |
| Northeastern University | Masters Business Admin |
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
| The University of North Carolina at Charlotte | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| REZOLUTE, INC. | Health Technology |
| AVROBIO, INC. | Health Technology |
| ENTRADA THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Health Technology |
